Boditech Media
-
PRESS RELEASE
Boditech Med Posts Q2 2025 Revenue of $30.74M (KRW 41.5B), Boosting Global Growth
Q2 2025 revenue of $30.74M (KRW 41.5B), up 14.5% YoY
-
PRESS RELEASE
Boditech Med Showcases Next-Gen Diagnostic Solutions at ADLM 2025, Expanding Presence in Americas
Highlights include AFIAS automated immunoassay platform and key products like IGRA-TB and PENKID
-
PRESS RELEASE
Boditech Med and HLB LifeCare Sign MOU to Develop AI-Based Chronic Disease Diagnostics
Aimed at early detection and improved accessibility through personalized diagnostics
-
PRESS RELEASE
Boditech Med’s Dengue Diagnostic Kits Selected by WHO Expert Review Panel for Diagnostics (ERPD)
Selected by WHO ERPD to support global dengue response efforts
-
PRESS RELEASE
Boditech Med Reports Strong Q1 2025 Performance with Double-Digit Growth
Q1 2025 consolidated revenue reaches $28.7 million (₩39.1 billion), operating profit $5.9 million (₩8.1 billion)
-
PRESS RELEASE
Boditech Med Unveils Next-Generation Infectious Disease Diagnostic Platforms at ESCMID Global 2025
Showcased point-of-care solutions for latent tuberculosis and infection differentiation using the AFIAS platform
-
PRESS RELEASE
Boditech Med Receives ANVISA Approval for Four Diagnostic Kits for Dengue Fever and Latent TB
Products classified as Class III high-risk medical devices; approved following local clinical performance evaluations
-
PRESS RELEASE
Boditech Med Holds Completion Ceremony for New Manufacturing Plant in India
New factory established in Jhajjar, India to enhance price competitiveness through local production
-
PRESS RELEASE
Boditech Med Showcases Innovative IVD Solutions at CACLP 2025 in China
Cardiovascular and acute chest pain diagnostic panel, featuring ST2 & NT-proBNP, draws significant attention
-
PRESS RELEASE
Boditech Med Receives Approval for Seven AFIAS Diagnostic Kits from Russia’s Health Authority
Certification completed for seven AFIAS kits: four for cardiovascular diseases and three for inflammatory markers